Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Meeting abstract

Comparison between adherence assessments and blood glucose monitoring measures to predict A1c in type 1 diabetes

Authors: Gabriela Heiden Teló, Martina Schaan de Souza, Thaís Sturmer Andrade, Beatriz D'Agord Schaan

Published in: Diabetology & Metabolic Syndrome | Special Issue 1/2015

Login to get access

Excerpt

Treatment adherence is crucial in patients with diabetes; however, there is disagreement on how to measure adherence in adults with type 1 diabetes (T1D). Surveys have been validated to evaluate adherence, and several studies have demonstrated a strong correlation between frequency of blood glucose monitoring (BGM) and glycemic control. …
Metadata
Title
Comparison between adherence assessments and blood glucose monitoring measures to predict A1c in type 1 diabetes
Authors
Gabriela Heiden Teló
Martina Schaan de Souza
Thaís Sturmer Andrade
Beatriz D'Agord Schaan
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue Special Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-S1-A170

Other articles of this Special Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine